$Global Checkpoint Inhibitor Refractory Cancer Market Report 2025$

Item added to cart!

Published : December 2025

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Checkpoint Inhibitor Refractory Cancer Global Market Report 2025

Name: Checkpoint Inhibitor Refractory Cancer Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Therapy (Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies ), By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types), By Mechanism Of Action (Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions), By Administration Route (Intravenous (IV), Oral), By End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Checkpoint Inhibitor Refractory Cancer Market Overview

• Checkpoint Inhibitor Refractory Cancer market size has reached to $32.81 billion in 2024

• Expected to grow to $56.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%

• Growth Driver: Rising Incidence Of Cancer Driving The Growth Of The Market Due To An Aging Population

• Market Trend: Technological Advancements And Early-Phase Clinical Data In Checkpoint Inhibitor Refractory Cancer Market

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Checkpoint Inhibitor Refractory Cancer Market?

Checkpoint inhibitor refractory cancer is a type of cancer that fails to respond to immune checkpoint inhibitors such as PD-1, PD-L1, or CTLA-4 blockers. This can occur as primary resistance, where there is no initial response, or as acquired resistance, where the cancer progresses after an initial benefit. Managing these cases often requires alternative treatments, such as combination immunotherapy, targeted agents, or novel experimental strategies.

The main therapies for checkpoint inhibitor refractory cancer include Immune Checkpoint Inhibitors, combination therapies, and targeted therapies. Immune checkpoint inhibitors are medicines that help the immune system recognize and attack cancer cells by blocking proteins that stop immune cells from working properly. It is used for various cancer types such as non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, triple-negative breast cancer (TNBC), colorectal cancer, and others. The various mechanisms of action include programmed cell death protein (PD)-1 inhibitors, programmed death-ligand (PD)-l1 inhibitors, cytotoxic T-lymphocyte–associated protein (CTLA)-4 inhibitors, and others. and the various routes of administration involved are intravenous (IV) and oral. It is used by several end users, including hospital pharmacies, retail pharmacies, and online pharmacies.

$Checkpoint Inhibitor Refractory Cancer Market Size and growth rate 2025 to 2029: Graph$

What Is The Checkpoint Inhibitor Refractory Cancer Market Size 2025 And Growth Rate?

What Is The Checkpoint Inhibitor Refractory Cancer Market Growth Forecast?

The checkpoint inhibitor refractory cancer market size is expected to see rapid growth in the next few years. It will grow to $56.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to the growing number of diagnoses, growing demand for personalized medicine, expanding indications for checkpoint inhibitors, rising geriatric population, and increasing use of biomarkers for patient selection. Major trends in the forecast period include advancements in combination therapies, next-generation checkpoint inhibitors, integration of AI in treatment planning, oral checkpoint inhibitors, and development of personalized cancer vaccines.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Checkpoint Inhibitor Refractory Cancer Market Segmented?

1) By Therapy: Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies

2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types

3) By Mechanism Of Action: Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions

4) By Administration Route: Intravenous (IV), Oral

5) By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Combination Therapies: Checkpoint Inhibitor + Chemotherapy, Checkpoint Inhibitor + Targeted Therapy, Checkpoint Inhibitor + Other Immunotherapies, Dual Checkpoint Inhibitor Combinations

3) By Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies Targeting Specific Cancer Markers

What Is Driving The Checkpoint Inhibitor Refractory Cancer Market? Rising Incidence Of Cancer Driving The Growth Of The Market Due To An Aging Population

The rising incidence of cancer is expected to propel the growth of the checkpoint inhibitor refractory cancer market going forward. Cancer refers to a disease characterized by the uncontrolled division and growth of abnormal cells in the body. The rising incidence of cancer is mainly due to an aging population, as longer life expectancy increases the likelihood of developing cancer over time. Recognizing checkpoint inhibitor refractory cancer is valuable in cancer management, as it enables early detection of treatment resistance, guiding clinicians to promptly modify therapy and pursue alternative approaches that may enhance patient outcomes. For instance, in February 2025, according to the United Nations, a US-based intergovernmental organization, an estimated 2.3 million new breast cancer cases were diagnosed in 2022, resulting in 670,000 deaths, and global projections indicate a 38% increase in cases and a 68% rise in annual deaths by 2050. Therefore, the rising incidence of cancer is driving the growth of the checkpoint inhibitor refractory cancer industry.

Who Are The Major Players In The Global Checkpoint Inhibitor Refractory Cancer Market?

Major companies operating in the checkpoint inhibitor refractory cancer market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., and Pliant Therapeutics Inc.

What Are The Key Trends Of The Global Checkpoint Inhibitor Refractory Cancer Market? Technological Advancements And Early-Phase Clinical Data In Checkpoint Inhibitor Refractory Cancer Market

Major companies operating in the checkpoint inhibitor refractory cancer market are focusing on developing innovative products, such as dual selective inhibitors, to reduce the likelihood of drug resistance by targeting two critical pathways involved in disease progression. Dual selective inhibitors are compounds that block two distinct biological targets or pathways at the same time while limiting impact on other unrelated pathways. For instance, in March 2025, Pliant Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors. Pliant Therapeutics’ interim Phase 1 data for PLN-101095 in patients with immune checkpoint inhibitor–refractory advanced solid tumors demonstrated promising early activity and a manageable safety profile. At the highest tested dose of 1,000 mg twice daily combined with pembrolizumab, the trial reported a 50% objective response rate, including confirmed partial responses in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, showing significant tumor reductions. PLN-101095 was generally well tolerated, with most treatment-emergent adverse events being mild to moderate. The study is ongoing, with higher-dose cohorts currently enrolling and additional data expected by the end of 2025.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Checkpoint Inhibitor Refractory Cancer Market? Bristol-Myers Squibb Acquired Mirati Therapeutics To Expand Oncology Portfolio

In October 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical industry company, acquired Mirati Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol Myers Squibb aims to strengthen and diversify its oncology portfolio by integrating Mirati’s innovative cancer therapies and clinical-stage assets, particularly targeting KRAS-mutated cancers and checkpoint inhibitor refractory cancers. Mirati Therapeutics Inc. is a US-based provider of therapies specifically designed for checkpoint inhibitor refractory (resistant) cancers.

What Is The Regional Outlook For The Global Checkpoint Inhibitor Refractory Cancer Market?

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Checkpoint Inhibitor Refractory Cancer Market?

The checkpoint inhibitor refractory cancer market includes revenues earned by entities by providing services such as diagnostic and biomarker services, clinical trials and research services, specialized oncology treatment services, and patient support and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The checkpoint inhibitor refractory cancer market consists of sales of tumor-infiltrating lymphocyte (TIL) therapy kits, genomic sequencing panels, tumor organoids, drug discovery tools, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Checkpoint Inhibitor Refractory Cancer Industry?

The checkpoint inhibitor refractory cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitor refractory cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Checkpoint Inhibitor Refractory Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$36.69 billion
Revenue Forecast In 2034	$56.64 billion
Growth Rate	CAGR of 11.5% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	Therapy, Cancer Type, Mechanism Of Action, Administration Route, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., and Pliant Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Checkpoint Inhibitor Refractory Cancer Market Characteristics

3. Checkpoint Inhibitor Refractory Cancer Market Trends And Strategies

4. Checkpoint Inhibitor Refractory Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Checkpoint Inhibitor Refractory Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Checkpoint Inhibitor Refractory Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Checkpoint Inhibitor Refractory Cancer Market Growth Rate Analysis

5.4. Global Checkpoint Inhibitor Refractory Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Checkpoint Inhibitor Refractory Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Checkpoint Inhibitor Refractory Cancer Total Addressable Market (TAM)

6. Checkpoint Inhibitor Refractory Cancer Market Segmentation

6.1. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immune Checkpoint Inhibitors

Combination Therapies

Targeted Therapies

6.2. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Non-Small Cell Lung Cancer (NSCLC)

Melanoma

Renal Cell Carcinoma (RCC)

Head And Neck Squamous Cell Carcinoma (HNSCC)

Urothelial Carcinoma

Triple-Negative Breast Cancer (TNBC)

Colorectal Cancer

Other Cancer Types

6.3. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Programmed Cell Death Protein (PD)-1 Inhibitors

Programmed Death-Ligand (PD)-L1 Inhibitors

Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors

Other Mechanism Of Actions

6.4. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous (IV)

Oral

6.5. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.6. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors (ICIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

PD-1 Inhibitors

PD-L1 Inhibitors

CTLA-4 Inhibitors

6.7. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Checkpoint Inhibitor + Chemotherapy

Checkpoint Inhibitor + Targeted Therapy

Checkpoint Inhibitor + Other Immunotherapies

Dual Checkpoint Inhibitor Combinations

6.8. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tyrosine Kinase Inhibitors (TKIs)

Monoclonal Antibodies Targeting Specific Cancer Markers

7. Checkpoint Inhibitor Refractory Cancer Market Regional And Country Analysis

7.1. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market

8.1. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Checkpoint Inhibitor Refractory Cancer Market

9.1. China Checkpoint Inhibitor Refractory Cancer Market Overview

9.2. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Checkpoint Inhibitor Refractory Cancer Market

10.1. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Checkpoint Inhibitor Refractory Cancer Market

11.1. Japan Checkpoint Inhibitor Refractory Cancer Market Overview

11.2. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Checkpoint Inhibitor Refractory Cancer Market

12.1. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Checkpoint Inhibitor Refractory Cancer Market

13.1. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Checkpoint Inhibitor Refractory Cancer Market

14.1. South Korea Checkpoint Inhibitor Refractory Cancer Market Overview

14.2. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Checkpoint Inhibitor Refractory Cancer Market

15.1. Western Europe Checkpoint Inhibitor Refractory Cancer Market Overview

15.2. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Checkpoint Inhibitor Refractory Cancer Market

16.1. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Checkpoint Inhibitor Refractory Cancer Market

17.1. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Checkpoint Inhibitor Refractory Cancer Market

18.1. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Checkpoint Inhibitor Refractory Cancer Market

19.1. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Checkpoint Inhibitor Refractory Cancer Market

20.1. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market

21.1. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market Overview

21.2. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Checkpoint Inhibitor Refractory Cancer Market

22.1. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Checkpoint Inhibitor Refractory Cancer Market

23.1. North America Checkpoint Inhibitor Refractory Cancer Market Overview

23.2. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Checkpoint Inhibitor Refractory Cancer Market

24.1. USA Checkpoint Inhibitor Refractory Cancer Market Overview

24.2. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Checkpoint Inhibitor Refractory Cancer Market

25.1. Canada Checkpoint Inhibitor Refractory Cancer Market Overview

25.2. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Checkpoint Inhibitor Refractory Cancer Market

26.1. South America Checkpoint Inhibitor Refractory Cancer Market Overview

26.2. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Checkpoint Inhibitor Refractory Cancer Market

27.1. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Checkpoint Inhibitor Refractory Cancer Market

28.1. Middle East Checkpoint Inhibitor Refractory Cancer Market Overview

28.2. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Checkpoint Inhibitor Refractory Cancer Market

29.1. Africa Checkpoint Inhibitor Refractory Cancer Market Overview

29.2. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape And Company Profiles

30.1. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape

30.2. Checkpoint Inhibitor Refractory Cancer Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Checkpoint Inhibitor Refractory Cancer Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. Bristol-Myers Squibb Company

31.3. AstraZeneca PLC

31.4. GlaxoSmithKline Plc

31.5. Eli Lilly and Company

31.6. Gilead Sciences Inc.

31.7. Amgen Inc.

31.8. Regeneron Pharmaceuticals Inc.

31.9. Eisai Co. Ltd.

31.10. Exelixis Inc.

31.11. Exicure Inc.

31.12. ImmunityBio Inc.

31.13. ENB Therapeutics Inc.

31.14. Kartos Therapeutics Inc.

31.15. Pliant Therapeutics Inc.

32. Global Checkpoint Inhibitor Refractory Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Checkpoint Inhibitor Refractory Cancer Market

34. Recent Developments In The Checkpoint Inhibitor Refractory Cancer Market

35. Checkpoint Inhibitor Refractory Cancer Market High Potential Countries, Segments and Strategies

35.1 Checkpoint Inhibitor Refractory Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 Checkpoint Inhibitor Refractory Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 Checkpoint Inhibitor Refractory Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors (ICIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Pfizer Inc. Financial Performance

Table 80: Johnson & Johnson Private Limited Financial Performance

Table 81: Merck & Co. Inc. Financial Performance

Table 82: AbbVie Inc. Financial Performance

Table 83: Novartis International AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors (ICIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Pfizer Inc. Financial Performance

Figure 80: Johnson & Johnson Private Limited Financial Performance

Figure 81: Merck & Co. Inc. Financial Performance

Figure 82: AbbVie Inc. Financial Performance

Figure 83: Novartis International AG Financial Performance

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Waterproofing Chemicals Global Market Report 2025 – By Product (Bitumen, Elastomers, PVC, TPO, EPDM), By Technology (Preformed Membranes, Coatings and LAMS (Liquid Applied Membrane Systems), Integral Systems), By Applica...

Water Infrastructure Repair Technologies Global Market Report 2025 – By Product (Flanges, Valves, Fittings, Pipes And Connectors, Couplings), By Repair Technology (Remote Assessment And Monitoring, Open And Cut-Pipe Repa...

Water Storage Systems Global Market Report 2025 – By Material (Steel, Fiberglass, Concrete, Plastic, Other Materials), By Location (Underground, Indoor, Outdoor), By Application (Hydraulic Fracture Storage And Collection...

Waterproof Tapes Global Market Report 2025 – By Resin Types (Acrylic, Butyl, Silicone, Other Resin Types), By Substrate Types (Plastic, Metal, Rubber, Other Substrate Types), By End-Use Industry (Electrical and Electroni...

Digital Water Solution Global Market Report 2025 – By Solutions (Hardware, Software, Services), By Technology (Metering And Customer Management, Network Management, Work And Asset Management, Plant Management, Informatio...

Water Testing Equipment Global Market Report 2025 – By Device Type (Stationary Or Bench-Top, Portable), By Test Type (pH Test, Dissolved Oxygen Test, Conductivity Test, Turbidity Test, T.D.C. Tests (Total Dissolved Conte...

Deionized Water Systems Global Market Report 2025 – By Type (Two Bed Deionized Water System, Mixed Bed Deionized Water System, Electrodeionization Water System), By Distribution Channel (Direct Sales, Distributors), By E...

Frequently Asked Questions

What is the definition of the Checkpoint Inhibitor Refractory Cancer market?

How will the Checkpoint Inhibitor Refractory Cancer market drivers and restraints affect the market dynamics? What forces will shape the Checkpoint Inhibitor Refractory Cancer industry going forward?

The market major growth driver - Rising Incidence Of Cancer Driving The Growth Of The Market Due To An Aging Population. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Checkpoint Inhibitor Refractory Cancer market?

The checkpoint inhibitor refractory cancer market size has grown rapidly in recent years. It will grow from $32.81 billion in 2024 to $36.69 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increasing prevalence of cancer, growing awareness of checkpoint inhibitors, expansion of cancer screenings, increasing clinical trial activities, and increasing demand for personalized treatments. The checkpoint inhibitor refractory cancer market size is expected to see rapid growth in the next few years. It will grow to $56.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to the growing number of diagnoses, growing demand for personalized medicine, expanding indications for checkpoint inhibitors, rising geriatric population, and increasing use of biomarkers for patient selection. Major trends in the forecast period include advancements in combination therapies, next-generation checkpoint inhibitors, integration of AI in treatment planning, oral checkpoint inhibitors, and development of personalized cancer vaccines. For further insights on this market, request a sample here

How is the Checkpoint Inhibitor Refractory Cancer market segmented?

The checkpoint inhibitor refractory cancer market covered in this report is segmented
1) By Therapy: Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies
2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types
3) By Mechanism Of Action: Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions
4) By Administration Route: Intravenous (IV), Oral
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments:
1) By Immune Checkpoint Inhibitors (ICIs): PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Combination Therapies: Checkpoint Inhibitor + Chemotherapy, Checkpoint Inhibitor + Targeted Therapy, Checkpoint Inhibitor + Other Immunotherapies, Dual Checkpoint Inhibitor Combinations
3) By Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies Targeting Specific Cancer Markers For further insights on this market, request a sample here

Which region has the largest share of the Checkpoint Inhibitor Refractory Cancer market? What are the other regions covered in the report?

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the checkpoint inhibitor refractory cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Checkpoint Inhibitor Refractory Cancer market?

What are the key trends in the Checkpoint Inhibitor Refractory Cancer market?

Major trends in this market include Technological Advancements And Early-Phase Clinical Data In Checkpoint Inhibitor Refractory Cancer Market. For further insights on this market, request a sample here.